shortagewatch

Home / Companies / 岩城製薬

Company family

岩城製薬: medicine shortages

As of 2 Nov 2026, 13 岩城製薬 products have a reported shortage across 1 countries, covering 11 medicines.

Products short13rank #151 of 464
Medicines11active ingredients
Countries1/16
New in 90 days1-7 vs market pace
Typical duration10 monthsmedian so far
Manufacturing62%demand-driven 31%

Where

Japan13

Which therapeutic classes

Dermatologicals5Sensory organs2Genito-urinary system and sex hormones1Anti-infectives1Cancer and immune system1Respiratory system1

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
岩城製薬岩城製薬: Manufacturing problem 8 (62%)62%岩城製薬: Increased demand 4 (31%)31%岩城製薬: Active ingredient shortage 1 (8%)8%All companiesAll companies: Manufacturing problem 4,893 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,221 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

When its current shortages began

00112Dec: 1Jan ’25: 0Feb: 0FebMar: 0Apr: 0May: 1MayJun: 1Jul: 0Aug: 0AugSep: 1Oct: 0Nov: 1NovDec: 1Jan ’26: 2Feb: 0FebMar: 0Apr: 0May: 2MayJun: 0Jul: 2Aug: 0AugSep: 1Oct: 0Nov: 0Nov

Against its peers

Viatris995Teva903Sandoz599Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158岩城製薬13

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 599 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 151 / 74Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7岩城製薬: 13 / 11岩城製薬

Further right: more products short. Higher: more different medicines affected.

Medicines short

MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Adapalene118 Dec 2025Manufacturing problem1/16
Alclometasone116 May 2025Active ingredient shortage1/16
Bifonazole15 Jan 2026Manufacturing problem3/16
Clindamycin17 Nov 2025Manufacturing problem4/16
Clotrimazole15 Jan 2026Manufacturing problem2/16
Formoterol and Mometasone125 Sep 2026Increased demand1/16
Gentamicin129 May 2026Increased demand1/16
Ketoconazole12 Dec 2024Increased demand1/16
Luliconazole122 Jul 2026Manufacturing problem1/16
Tacrolimus123 Jul 2026Increased demand6/16
Terbinafine113 May 2026Manufacturing problem5/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.